<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34946726</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>24</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease and Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7643</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules26247643</ELocationID><Abstract><AbstractText>Cannabinoids act as pleiotropic compounds exerting, among others, a broad-spectrum of neuroprotective effects. These effects have been investigated in the last years in different preclinical models of neurodegeneration, with the cannabinoid type-1 (CB<sub>1</sub>) and type-2 (CB<sub>2</sub>) receptors concentrating an important part of this research. However, the issue has also been extended to additional targets that are also active for cannabinoids, such as the orphan G-protein receptor 55 (GPR55). In the present study, we investigated the neuroprotective potential of VCE-006.1, a chromenopyrazole derivative with biased orthosteric and positive allosteric modulator activity at GPR55, in murine models of two neurodegenerative diseases. First, we proved that VCE-006.1 alone could induce ERK1/2 activation and calcium mobilization, as well as increase cAMP response but only in the presence of lysophosphatidyl inositol. Next, we investigated this compound administered chronically in two neurotoxin-based models of Parkinson's disease (PD), as well as in some cell-based models. VCE-006.1 was active in reversing the motor defects caused by 6-hydroxydopamine (6-OHDA) in the pole and the cylinder rearing tests, as well as the losses in tyrosine hydroxylase-containing neurons and the elevated glial reactivity detected in the substantia nigra. Similar cytoprotective effects were found in vitro in SH-SY5Y cells exposed to 6-OHDA. We also investigated VCE-006.1 in LPS-lesioned mice with similar beneficial effects, except against glial reactivity and associated inflammatory events, which remained unaltered, a fact confirmed in BV2 cells treated with LPS and VCE-006.1. We also analyzed GPR55 in these in vivo models with no changes in its gene expression, although GPR55 was down-regulated in BV2 cells treated with LPS, which may explain the lack of efficacy of VCE-006.1 in such an assay. Furthermore, we investigated VCE-006.1 in two genetic models of amyotrophic lateral sclerosis (ALS), mutant SOD1, or TDP-43 transgenic mice. Neither the neurological decline nor the deteriorated rotarod performance were prevented with this compound, and the same happened with the elevated microglial and astroglial reactivities, albeit modest spinal motor neuron preservation was achieved in both models. We also analyzed GPR55 in these in vivo models and found no changes in both TDP-43 transgenic and mSOD1 mice. Therefore, our findings support the view that targeting the GPR55 may afford neuroprotection in experimental PD, but not in ALS, thus stressing the specificities for the development of cannabinoid-based therapies in the different neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burgaz</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Concepci&#xf3;n</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2482-1148</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalo-Consuegra</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Almer&#xed;a</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Pino</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Emerald Health Biotechnology Espa&#xf1;a, 14014 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unciti</LastName><ForeName>Juan Diego</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Emerald Health Biotechnology Espa&#xf1;a, 14014 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Ca&#xf1;as</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2520-948X</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcalde</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7959-6876</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6209-8600</Identifier><AffiliationInfo><Affiliation>Instituto de Qu&#xed;mica M&#xe9;dica, CSIC, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagerovic</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-2642-6969</Identifier><AffiliationInfo><Affiliation>Instituto de Qu&#xed;mica M&#xe9;dica, CSIC, 28006 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Cueto</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lago</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6260-3777</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8478-5842</Identifier><AffiliationInfo><Affiliation>Emerald Health Biotechnology Espa&#xf1;a, 14014 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Maim&#xf3;nides de Investigaci&#xf3;n Biom&#xe9;dica de C&#xf3;rdoba (IMIBIC), 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Biology, Physiology and Immunology, University of C&#xf3;rdoba, 14071 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Universitario Reina Sof&#xed;a, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Ruiz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4490-0604</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C524885">GPR55 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C526692">GPR55 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043882">Receptors, Cannabinoid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043882" MajorTopicYN="N">Receptors, Cannabinoid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020298" MajorTopicYN="N">U937 Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">6-hydroxydopamine</Keyword><Keyword MajorTopicYN="N">GPR55 receptors</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">TDP-43 transgenic mice</Keyword><Keyword MajorTopicYN="N">VCE-006.1</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">chromenopyrazole</Keyword><Keyword MajorTopicYN="N">lipopolysaccharide</Keyword><Keyword MajorTopicYN="N">mSOD1 mice</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34946726</ArticleId><ArticleId IdType="pmc">PMC8708356</ArticleId><ArticleId IdType="doi">10.3390/molecules26247643</ArticleId><ArticleId IdType="pii">molecules26247643</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fern&#xe1;ndez-Ruiz J., Moro M.A., Martinez-Orgado J. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics. 2015;12:793&#x2013;806. doi: 10.1007/s13311-015-0381-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0381-7</ArticleId><ArticleId IdType="pmc">PMC4604192</ArticleId><ArticleId IdType="pubmed">26260390</ArticleId></ArticleIdList></Reference><Reference><Citation>Aymerich M.S., Aso E., Abellanas M.A., Tolon R.M., Ramos J.A., Ferrer I., Romero J., Fern&#xe1;ndez-Ruiz J. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem. Pharmacol. 2018;157:67&#x2013;84. doi: 10.1016/j.bcp.2018.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2018.08.016</ArticleId><ArticleId IdType="pubmed">30121249</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz J. The biomedical challenge of neurodegenerative disorders: An opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. Br. J. Pharmacol. 2018;176:1370&#x2013;1383. doi: 10.1111/bph.14382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14382</ArticleId><ArticleId IdType="pmc">PMC6487558</ArticleId><ArticleId IdType="pubmed">29856067</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarlone A., Bellocchio L., Bl&#xe1;zquez C., Resel E., Soria-G&#xf3;mez E., Cannich A., Ferrero J.J., Sagredo O., Benito C., Romero J., et al. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci USA. 2014;111:8257&#x2013;8262. doi: 10.1073/pnas.1400988111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1400988111</ArticleId><ArticleId IdType="pmc">PMC4050577</ArticleId><ArticleId IdType="pubmed">24843137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiebel C., Behl C. The complex modulation of lysosomal degradation pathways by cannabinoid receptors 1 and 2. Life Sci. 2015;138:3&#x2013;7. doi: 10.1016/j.lfs.2015.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2015.03.020</ArticleId><ArticleId IdType="pubmed">25908257</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso E., Palomer E., Juv&#xe9;s S., Maldonado R., Mu&#xf1;oz F.J., Ferrer I. CB1 Agonist ACEA Protects Neurons and Reduces the Cognitive Impairment of A&#x3b2;PP/PS1 Mice. J. Alzheimer&#x2019;s Dis. 2012;30:439&#x2013;459. doi: 10.3233/JAD-2012-111862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-111862</ArticleId><ArticleId IdType="pubmed">22451318</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro G., Borroto-Escuela D., Angelats E., Etayo &#xcd;., Reyes-Resina I., Pulido-Salgado M., Rodr&#xed;guez-P&#xe9;rez A.I., Canela E.I., Saura J., Lanciego J.L., et al. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer&#x2019;s disease and levodopa-induced dyskinesia. Brain Behav Immun. 2018;67:139&#x2013;151. doi: 10.1016/j.bbi.2017.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.08.015</ArticleId><ArticleId IdType="pubmed">28843453</ArticleId></ArticleIdList></Reference><Reference><Citation>Crunfli F., Vrechi T.A., Costa A.P., Torr&#xe3;o A.S. Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity Through Apoptosis Pathway and NO Modulation. Neurotox. Res. 2019;35:516&#x2013;529. doi: 10.1007/s12640-018-9991-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-018-9991-2</ArticleId><ArticleId IdType="pubmed">30607903</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.C., Bok E., Huh S.H., Park J.Y., Yoon S.H., Kim S.R., Kim Y.S., Maeng S., Park S.H., Jin B.K. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J. Immunol. 2011;187:6508&#x2013;6517. doi: 10.4049/jimmunol.1102435.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102435</ArticleId><ArticleId IdType="pubmed">22079984</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Rial S., Garc&#xed;a-Guti&#xe9;rrez M.S., Molina J.A., P&#xe9;rez-Nievas B.G., Ledent C., Leiva C., Leza J.C., Manzanares J. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiol. Aging. 2011;32:631&#x2013;645. doi: 10.1016/j.neurobiolaging.2009.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.03.017</ArticleId><ArticleId IdType="pubmed">19419794</ArticleId></ArticleIdList></Reference><Reference><Citation>Abood M.E., Rizvi G., Sallapudi N., McAllister S.D. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 2001;309:197&#x2013;201. doi: 10.1016/S0304-3940(01)02065-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)02065-1</ArticleId><ArticleId IdType="pubmed">11514075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P., Ignacio S., Beattie E.C., Abood M.E. Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: Implications for excitotoxicity. Eur. J. Neurosci. 2008;27:572&#x2013;579. doi: 10.1111/j.1460-9568.2008.06041.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2008.06041.x</ArticleId><ArticleId IdType="pmc">PMC3991137</ArticleId><ArticleId IdType="pubmed">18279310</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S., De Chiara V., Musella A., Cozzolino M., Bernardi G., Maccarrone M., Mercuri N.B., Carr&#xec; M.T., Centonze D. Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;11:83&#x2013;90. doi: 10.3109/17482960902977954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902977954</ArticleId><ArticleId IdType="pubmed">19452308</ArticleId></ArticleIdList></Reference><Reference><Citation>Bl&#xe1;zquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., Palazuelos J., Julien B., Salazar M., B&#xf6;rner C., et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington&#x2019;s disease. Brain. 2011;134:119&#x2013;136. doi: 10.1093/brain/awq278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq278</ArticleId><ArticleId IdType="pubmed">20929960</ArticleId></ArticleIdList></Reference><Reference><Citation>Maya-L&#xf3;pez M., Col&#xed;n-Gonz&#xe1;lez A.L., Aguilera G., De Lima M.E., Colpo-Ceolin A., Rangel-Lopez E., Villeda-Hern&#xe1;ndez J., Rembao-Boj&#xf3;rquez D., T&#xfa;nez I., Luna-L&#xf3;pez A., et al. Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: Involvement of CB1 and NMDA receptors. Am. J. Transl. Res. 2017;9:261&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340665</ArticleId><ArticleId IdType="pubmed">28337258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Calvo A., Maroto I.B., Bajo-Gra&#xf1;eras R., Chiarlone A., Gaudioso &#xc1;., Ferrero J.J., Resel E., S&#xe1;nchez-Prieto J., Rodr&#xed;guez-Navarro J.A., Marsicano G., et al. Pathway-specific control of striatal neuron vulnerability by corticostriatal cannabinoid CB1 receptors. Cereb. Cortex. 2018;28:307&#x2013;322. doi: 10.1093/cercor/bhx285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhx285</ArticleId><ArticleId IdType="pubmed">29121220</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S., Furlan R., De Chiara V., Muzio L., Musella A., Motta C., Studer V., Cavasinni F., Bernardi G., Martino G., et al. Cannabinoid CB1 receptors regulate neuronal TNF-&#x3b1; effects in experimental autoimmune encephalomyelitis. Brain Behav. Immun. 2011;25:1242&#x2013;1248. doi: 10.1016/j.bbi.2011.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2011.03.017</ArticleId><ArticleId IdType="pubmed">21473912</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martet M., Feli&#xfa; A., Espejo-Porras F., Mecha M., Carrillo-Salinas F.J., Fern&#xe1;ndez-Ruiz J., Guaza C., de Lago E. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to &#x394;9-tetrahydrocannabinol acting through CB1 receptors. Mult. Scler. Relat. Disord. 2015;4:505&#x2013;511. doi: 10.1016/j.msard.2015.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2015.08.001</ArticleId><ArticleId IdType="pubmed">26590655</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz J., Romero J., Velasco G., Tol&#xf3;n R.M., Ramos J.A., Guzm&#xe1;n M. Cannabinoid CB2 receptor: A new target for controlling neural cell survival? Trends Pharmacol. Sci. 2007;28:39&#x2013;45. doi: 10.1016/j.tips.2006.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2006.11.001</ArticleId><ArticleId IdType="pubmed">17141334</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso E., Ferrer I. CB2 Cannabinoid Receptor As Potential Target against Alzheimer&#x2019;s Disease. Front. Neurosci. 2016;10:243. doi: 10.3389/fnins.2016.00243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00243</ArticleId><ArticleId IdType="pmc">PMC4885828</ArticleId><ArticleId IdType="pubmed">27303261</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez A., Aparicio N., Pazos M.R., Grande M.T., Barreda-Manso M.A., Benito-Cuesta I., V&#xe1;zquez C., Amores M., Ruiz-P&#xe9;rez G., Garc&#xed;a-Garc&#xed;a E., et al. Cannabinoid CB2 receptors in the mouse brain: Relevance for Alzheimer&#x2019;s disease. J. Neuroinflamm. 2018;15:158. doi: 10.1186/s12974-018-1174-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1174-9</ArticleId><ArticleId IdType="pmc">PMC5968596</ArticleId><ArticleId IdType="pubmed">29793509</ArticleId></ArticleIdList></Reference><Reference><Citation>Magham S.V., Krishnamurthy P.T., Shaji N., Mani L., Balasubramanian S. Cannabinoid receptor 2 selective agonists and Alzheimer&#x2019;s disease: An insight into the therapeutic potentials. J. Neurosci. Res. 2021;99:2888&#x2013;2905. doi: 10.1002/jnr.24933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24933</ArticleId><ArticleId IdType="pubmed">34486749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal&#xe1;n-Ganga M., Rodr&#xed;guez-Cueto C., Merch&#xe1;n-Rubira J., Hern&#xe1;ndez F., &#xc1;vila J., Posada-Ayala M., Lanciego J.L., Luengo E., Lopez M.G., R&#xe1;bano A., et al. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Acta Neuropathol. Commun. 2021;9:90. doi: 10.1186/s40478-021-01196-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01196-5</ArticleId><ArticleId IdType="pmc">PMC8130522</ArticleId><ArticleId IdType="pubmed">34001284</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a C., Palomo-Garo C., Garc&#xed;a-Arencibia M., Ramos J., Pertwee R., Fern&#xe1;ndez-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid &#x394;9-THCV in animal models of Parkinson&#x2019;s disease. Br. J. Pharmacol. 2011;163:1495&#x2013;1506. doi: 10.1111/j.1476-5381.2011.01278.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2011.01278.x</ArticleId><ArticleId IdType="pmc">PMC3165958</ArticleId><ArticleId IdType="pubmed">21323909</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-G&#xe1;lvez Y., Palomo-Garo C., Fern&#xe1;ndez-Ruiz J., Garc&#xed;a C. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson&#x2019;s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2016;64:200&#x2013;208. doi: 10.1016/j.pnpbp.2015.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2015.03.017</ArticleId><ArticleId IdType="pubmed">25863279</ArticleId></ArticleIdList></Reference><Reference><Citation>Javed H., Azimullah S., Haque M.E., Ojha S.K. Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson&#x2019;s Disease. Front. Neurosci. 2016;10:321. doi: 10.3389/fnins.2016.00321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00321</ArticleId><ArticleId IdType="pmc">PMC4969295</ArticleId><ArticleId IdType="pubmed">27531971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Cai Q., Zhang J., He X., Liu Y., Zhu R., Jin L. AM1241 alleviates MPTP-induced Parkinson&#x2019;s disease and promotes the regeneration of DA neurons in PD mice. Oncotarget. 2017;8:67837&#x2013;67850. doi: 10.18632/oncotarget.18871.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.18871</ArticleId><ArticleId IdType="pmc">PMC5620217</ArticleId><ArticleId IdType="pubmed">28978077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K., Moore D.H., Makriyannis A., Abood M.E. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol. 2006;542:100&#x2013;105. doi: 10.1016/j.ejphar.2006.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2006.05.025</ArticleId><ArticleId IdType="pubmed">16781706</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemaker J.L., Seely K.A., Reed R.L., Crow J.P., Prather P.L. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 2006;101:87&#x2013;98. doi: 10.1111/j.1471-4159.2006.04346.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04346.x</ArticleId><ArticleId IdType="pmc">PMC2819701</ArticleId><ArticleId IdType="pubmed">17241118</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo-Porras F., Garc&#xed;a-Toscano L., Rodr&#xed;guez-Cueto C., Santos-Garc&#xed;a I., de Lago E., Fernandez-Ruiz J. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br. J. Pharmacol. 2019;176:1585&#x2013;1600. doi: 10.1111/bph.14216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14216</ArticleId><ArticleId IdType="pmc">PMC6487601</ArticleId><ArticleId IdType="pubmed">29574689</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Cueto C., G&#xf3;mez-Almer&#xed;a M., Garc&#xed;a Toscano L., Romero J., Hillard C.J., de Lago E., Fern&#xe1;ndez-Ruiz J. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis. Brain. Pathol. 2021;31:e12972. doi: 10.1111/bpa.12972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12972</ArticleId><ArticleId IdType="pmc">PMC8549023</ArticleId><ArticleId IdType="pubmed">33983653</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Cueto C., Garc&#xed;a-Toscano L., Santos-Garc&#xed;a I., G&#xf3;mez-Almer&#xed;a M., Gonzalo-Consuegra C., Espejo-Porras F., Fern&#xe1;ndez-Ruiz J., de Lago E. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. Br. J. Pharmacol. 2021;178:1373&#x2013;1387. doi: 10.1111/bph.15386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15386</ArticleId><ArticleId IdType="pubmed">33486755</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagredo O., Gonz&#xe1;lez S., Aroyo I., Pazos M.R., Benito C., Lastres-Becker I., Romero J.P., Tol&#xf3;n R.M., Mechoulam R., Brouillet E., et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington&#x2019;s disease. Glia. 2009;57:1154&#x2013;1167. doi: 10.1002/glia.20838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20838</ArticleId><ArticleId IdType="pmc">PMC2706932</ArticleId><ArticleId IdType="pubmed">19115380</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazuelos J., Aguado T., Pazos M.R., Julien B., Carrasco C., Resel E., Sagredo O., Benito C., Romero J., Azcoitia I., et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington&#x2019;s disease excitotoxicity. Brain. 2009;132:3152&#x2013;3164. doi: 10.1093/brain/awp239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp239</ArticleId><ArticleId IdType="pubmed">19805493</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard J., Truong J., Bouchard K., Dunkelberger D., Desrayaud S., Moussaoui S., Tabrizi S.J., Stella N., Muchowski P.J. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington&#x2019;s disease. J. Neurosci. 2012;32:18259&#x2013;18268. doi: 10.1523/JNEUROSCI.4008-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4008-12.2012</ArticleId><ArticleId IdType="pmc">PMC3753072</ArticleId><ArticleId IdType="pubmed">23238740</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales P., G&#xf3;mez-Ca&#xf1;as M., Navarro G., Hurst D.P., Carrillo-Salinas F.J., Lagartera L., Pazos R., Goya P., Reggio P.H., Guaza C., et al. Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis. J. Med. Chem. 2016;59:6753&#x2013;6771. doi: 10.1021/acs.jmedchem.6b00397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b00397</ArticleId><ArticleId IdType="pmc">PMC5321205</ArticleId><ArticleId IdType="pubmed">27309150</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti T.B., Barbosa W.L., Vieira J.L., Raposo N.R., Dutra R.C. (-)-&#x3b2;-Caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis. Int. J. Mol. Sci. 2017;18:691. doi: 10.3390/ijms18040691.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18040691</ArticleId><ArticleId IdType="pmc">PMC5412277</ArticleId><ArticleId IdType="pubmed">28368293</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecha M., Carrillo-Salinas F.J., Feli&#xfa; A., Mestre L., Guaza C. Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review. Front. Cell. Neurosci. 2020;14:34. doi: 10.3389/fncel.2020.00034.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00034</ArticleId><ArticleId IdType="pmc">PMC7042204</ArticleId><ArticleId IdType="pubmed">32140100</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan S.E. An update on PPAR activation by cannabinoids. Br. J. Pharmacol. 2016;173:1899&#x2013;1910. doi: 10.1111/bph.13497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13497</ArticleId><ArticleId IdType="pmc">PMC4882496</ArticleId><ArticleId IdType="pubmed">27077495</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannotti F., Vitale R. The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation. Cells. 2021;10:586. doi: 10.3390/cells10030586.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10030586</ArticleId><ArticleId IdType="pmc">PMC8001692</ArticleId><ArticleId IdType="pubmed">33799988</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a C., G&#xf3;mez-Ca&#xf1;as M., Burgaz S., Palomares B., G&#xf3;mez-G&#xe1;lvez Y., Palomo-Garo C., Campo S., Ferrer-Hern&#xe1;ndez J., Pavicic C., Navarrete C., et al. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson&#x2019;s disease: Possible involvement of different binding sites at the PPAR&#x3b3; receptor. J. Neuroinflamm. 2018;15:19. doi: 10.1186/s12974-018-1060-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1060-5</ArticleId><ArticleId IdType="pmc">PMC5771072</ArticleId><ArticleId IdType="pubmed">29338785</ArticleId></ArticleIdList></Reference><Reference><Citation>Junior N.C.F., dos-Santos-Pereira M., Guimar&#xe3;es F.S., Del Bel E. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson&#x2019;s Disease and l-DOPA-Induced Dyskinesia. Neurotox. Res. 2020;37:12&#x2013;29. doi: 10.1007/s12640-019-00109-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-019-00109-8</ArticleId><ArticleId IdType="pubmed">31637586</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgaz S., Garc&#xed;a C., G&#xf3;mez-Ca&#xf1;as M., Rolland A., Mu&#xf1;oz E., Fern&#xe1;ndez-Ruiz J. Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson&#x2019;s Disease. Molecules. 2021;26:3245. doi: 10.3390/molecules26113245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26113245</ArticleId><ArticleId IdType="pmc">PMC8198479</ArticleId><ArticleId IdType="pubmed">34071302</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgaz S., Garc&#xed;a C., G&#xf3;mez-Ca&#xf1;as M., Navarrete C., Garc&#xed;a-Mart&#xed;n A., Rolland A., Del R&#xed;o C., Casarejos M.J., Mu&#xf1;oz E., Gonzalo-Consuegra C., et al. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson&#x2019;s disease using 6-hydroxydopamine-lesioned mice. Mol. Cell Neurosci. 2021;110:103583. doi: 10.1016/j.mcn.2020.103583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2020.103583</ArticleId><ArticleId IdType="pubmed">33338634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cueto C.R., Santos-Garc&#xed;a I., Garc&#xed;a-Toscano L., Espejo-Porras F., Bellido M., Fern&#xe1;ndez-Ruiz J., Munoz E., de Lago E. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochem. Pharmacol. 2018;157:217&#x2013;226. doi: 10.1016/j.bcp.2018.07.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2018.07.049</ArticleId><ArticleId IdType="pubmed">30076846</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhfouri G., Ahmadiani A., Rahimian R., Grolla A.A., Moradi F., Haeri A. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-&#x3b3; pathway. Neuropharmacology. 2012;63:653&#x2013;666. doi: 10.1016/j.neuropharm.2012.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2012.05.013</ArticleId><ArticleId IdType="pubmed">22634229</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Dong Z., Liu S. &#x3b2;-Caryophyllene Ameliorates the Alzheimer-Like Phenotype in APP/PS1 Mice through CB2 Receptor Activation and the PPAR&#x3b3; Pathway. Pharmacology. 2014;94:1&#x2013;12. doi: 10.1159/000362689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000362689</ArticleId><ArticleId IdType="pubmed">25171128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallendrusch S., Kremzow S., Nowicki M., Grabiec U., Winkelmann R., Benz A., Kraft R., Bechmann I., Dehghani F., Koch M. The G protein-coupled receptor 55 ligand l-&#x3b1;-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion. Glia. 2013;61:1822&#x2013;1831. doi: 10.1002/glia.22560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22560</ArticleId><ArticleId IdType="pubmed">24038453</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill J.D., Zuluaga-Ramirez V., Gajghate S., Winfield M., Sriram U., Rom S., Persidsky Y. Activation of GPR55 induces neuroprotection of hippocampal neurogenesis and immune responses of neural stem cells following chronic, systemic inflammation. Brain Behav. Immun. 2019;76:165&#x2013;181. doi: 10.1016/j.bbi.2018.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2018.11.017</ArticleId><ArticleId IdType="pmc">PMC6398994</ArticleId><ArticleId IdType="pubmed">30465881</ArticleId></ArticleIdList></Reference><Reference><Citation>Minamihata T., Takano K., Moriyama M., Nakamura Y. Lysophosphatidylinositol, an Endogenous Ligand for G Protein-Coupled Receptor 55, Has Anti-inflammatory Effects in Cultured Microglia. Inflammation. 2020;43:1971&#x2013;1987. doi: 10.1007/s10753-020-01271-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-020-01271-4</ArticleId><ArticleId IdType="pubmed">32519268</ArticleId></ArticleIdList></Reference><Reference><Citation>Celorrio M., Rojo-Bustamante E., Fern&#xe1;ndez-Su&#xe1;rez D., S&#xe1;ez E., Estella-Hermoso de Mendoza A., M&#xfc;ller C.E., Ram&#xed;rez M.J., Oyarz&#xe1;bal J., Franco R., Aymerich M.S. GPR55: A therapeutic target for Parkinson&#x2019;s disease? Neuropharmacology. 2017;125:319&#x2013;332. doi: 10.1016/j.neuropharm.2017.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2017.08.017</ArticleId><ArticleId IdType="pubmed">28807673</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Pinilla E., Aguinaga D., Navarro G., Rico A.J., Oyarz&#xe1;bal J., S&#xe1;nchez-Arias J.A., Lanciego J.L., Franco R. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson&#x2019;s Disease. Mol. Neurobiol. 2019;56:5900&#x2013;5910. doi: 10.1007/s12035-019-1495-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1495-4</ArticleId><ArticleId IdType="pubmed">30687889</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.S., Chen H., Sun H., Zhu J., Jew C.P., Wager-Miller J., Straiker A., Spencer C., Bradshaw H., Mackie K., et al. GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination. PLoS ONE. 2013;8:e60314. doi: 10.1371/journal.pone.0060314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060314</ArticleId><ArticleId IdType="pmc">PMC3614963</ArticleId><ArticleId IdType="pubmed">23565223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Zhou J., Lehmann C. GPR55-a putative &#x201c;type 3&#x201d; cannabinoid receptor in inflammation. J. Basic Clin. Physiol. Pharmacol. 2016;27:297&#x2013;302. doi: 10.1515/jbcpp-2015-0080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jbcpp-2015-0080</ArticleId><ArticleId IdType="pubmed">26669245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauckner J.E., Jensen J., Chen H.-Y., Lu H.-C., Hille B., Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA. 2008;105:2699&#x2013;2704. doi: 10.1073/pnas.0711278105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0711278105</ArticleId><ArticleId IdType="pmc">PMC2268199</ArticleId><ArticleId IdType="pubmed">18263732</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales P., Reggio P.H. An update on non-CB1, non-CB2 cannabinoid related G-protein-coupled receptors. Cannabis Cannabinoid Res. 2017;2:265&#x2013;273. doi: 10.1089/can.2017.0036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/can.2017.0036</ArticleId><ArticleId IdType="pmc">PMC5665501</ArticleId><ArticleId IdType="pubmed">29098189</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.Z., He L. Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein-coupled receptors. Psychopharmacology. 2017;234:1181&#x2013;1207. doi: 10.1007/s00213-017-4586-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-017-4586-9</ArticleId><ArticleId IdType="pubmed">28289782</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawzdargo M., Nguyen T., Lee D.K., Lynch K.R., Cheng R., Heng H.H.Q., George S.R., O&#x2019;Dowd B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, &amp; Psi;GPR53 and GPR55: GPR55 is extensively expressed in human brain. Mol. Brain Res. 1999;64:193&#x2013;198 . doi: 10.1016/S0169-328X(98)00277-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(98)00277-0</ArticleId><ArticleId IdType="pubmed">9931487</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhouayek M., Masquelier J., Muccioli G.G. Lysophosphatidylinositols, from Cell Membrane Constituents to GPR55 Ligands. Trends Pharmacol. Sci. 2018;39:586&#x2013;604. doi: 10.1016/j.tips.2018.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2018.02.011</ArticleId><ArticleId IdType="pubmed">29588059</ArticleId></ArticleIdList></Reference><Reference><Citation>Shore D.M., Reggio P.H. The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front. Pharmacol. 2015;6:69. doi: 10.3389/fphar.2015.00069.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2015.00069</ArticleId><ArticleId IdType="pmc">PMC4397721</ArticleId><ArticleId IdType="pubmed">25926795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 2009;30:156&#x2013;163. doi: 10.1016/j.tips.2008.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2008.12.004</ArticleId><ArticleId IdType="pubmed">19233486</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales P., Jagerovic N. Advances towards the Discovery of GPR55 Ligands. Curr. Med. Chem. 2016;23:2087&#x2013;2100. doi: 10.2174/0929867323666160425113836.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867323666160425113836</ArticleId><ArticleId IdType="pubmed">27109575</ArticleId></ArticleIdList></Reference><Reference><Citation>Marichal-Cancino B.A., Fajardo-Valdez A., Ruiz-Contreras A.E., Mendez-D&#xed;az M., Prospero-Garc&#xed;a O. Advances in the physiology of GPR55 in the Central Nervous System. Curr. Neuropharmacol. 2017;15:771&#x2013;778. doi: 10.2174/1570159X14666160729155441.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X14666160729155441</ArticleId><ArticleId IdType="pmc">PMC5771053</ArticleId><ArticleId IdType="pubmed">27488130</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge C.M., Balenga N.A., Kargl J., Andradas C., Brown A.J., Irving A., Sanchez C., Waldhoer M. Minireview: Recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol. Endocrinol. 2011;25:1835&#x2013;1848. doi: 10.1210/me.2011-1197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2011-1197</ArticleId><ArticleId IdType="pmc">PMC5417173</ArticleId><ArticleId IdType="pubmed">21964594</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales P., Whyte L.S., Chicharro R., G&#xf3;mez-Ca&#xf1;as M., Pazos M.R., Goya P., Irving A.J., Fern&#xe1;ndez-Ruiz J., Ross R.A., Jagerovic N. Identification of novel GPR55 modulators using cell-impedance-based label-free technology. J. Med. Chem. 2016;59:1840&#x2013;1853. doi: 10.1021/acs.jmedchem.5b01331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b01331</ArticleId><ArticleId IdType="pubmed">26789378</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagerovic N., Morales P., Ross R., Whyte L. Selective Modulators of the Activity of the gpr55 Receptor: Chromenopyrazole Derivatives. WO2016177922A1. Patent. 2016 April 27;</Citation></Reference><Reference><Citation>Szliszka E., Czuba Z.P., Domino M., Mazur B., Zydowicz G., Krol W. Ethanolic Extract of Propolis (EEP) Enhances the Apoptosis- Inducing Potential of TRAIL in Cancer Cells. Molecules. 2009;14:738&#x2013;754. doi: 10.3390/molecules14020738.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules14020738</ArticleId><ArticleId IdType="pmc">PMC6254026</ArticleId><ArticleId IdType="pubmed">19223822</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietr M., Kozela E., Levy R., Rimmerman N., Lin Y.H., Stella N., Vogel Z., Juknat A. Differential changes in GPR55 during microglial cell activation. FEBS Lett. 2009;583:2071&#x2013;2076. doi: 10.1016/j.febslet.2009.05.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.05.028</ArticleId><ArticleId IdType="pubmed">19464294</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Vera D., Rosell-Valle C., L&#xf3;pez-Gambero A., Navarro J., Zambrana-Infantes E., Rivera P., Sant&#xed;n L., Suarez J., De Fonseca F.R. Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer&#x2019;s Disease in a Preclinical Model: A Therapeutic Opportunity. Biology. 2020;9:377. doi: 10.3390/biology9110377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology9110377</ArticleId><ArticleId IdType="pmc">PMC7694492</ArticleId><ArticleId IdType="pubmed">33167441</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X., Wang X., Jin S., Hu J., Wu Y., Li Y., Wu X. Activation of GPR55 attenuates cognitive impairment and neurotoxicity in a mouse model of Alzheimer&#x2019;s disease induced by A&#x3b2;1&#x2013;42 through inhibiting RhoA/ROCK2 pathway. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2021;112:110423. doi: 10.1016/j.pnpbp.2021.110423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2021.110423</ArticleId><ArticleId IdType="pubmed">34363866</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Pinilla E., Rico A.J., Rivas-Santisteban R., Lillo J., Roda E., Navarro G., Lanciego J.L., Franco R. Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates. Brain Struct. Funct. 2020;225:2153&#x2013;2164. doi: 10.1007/s00429-020-02116-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-020-02116-4</ArticleId><ArticleId IdType="pubmed">32691218</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatemi I., Abdollahi A., Shamsizadeh A., Allahtavakoli M., Roohbakhsh A. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson&#x2019;s disease rat model. Acta Neuropsychiatr. 2020;33:15&#x2013;21. doi: 10.1017/neu.2020.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/neu.2020.30</ArticleId><ArticleId IdType="pubmed">32967746</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek N., Popiolek-Barczyk K., Mika J., Przewlocka B., Starowicz K. Anandamide, Acting viaCB2Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures. Neural Plast. 2015;2015:1&#x2013;10. doi: 10.1155/2015/130639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/130639</ArticleId><ArticleId IdType="pmc">PMC4452105</ArticleId><ArticleId IdType="pubmed">26090232</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martet M., Espejo-Porras F., Fern&#xe1;ndez-Ruiz J., de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex&#xae;-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci. 2014;20:809&#x2013;815. doi: 10.1111/cns.12262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12262</ArticleId><ArticleId IdType="pmc">PMC6493201</ArticleId><ArticleId IdType="pubmed">24703394</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., H&#xf6;glinger G.U., Oertel W.H., Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson&#x2019;s disease in wild type and &#x3b1;-synuclein-deleted mice. Exp. Neurol. 2008;210:182&#x2013;193. doi: 10.1016/j.expneurol.2007.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.10.012</ArticleId><ArticleId IdType="pubmed">18053987</ArticleId></ArticleIdList></Reference><Reference><Citation>Palkovits M., Browstein J. Maps and Guide to Microdissection of the Rat Brain. Elsevier; Amsterdam, The Netherlands: 1988.</Citation></Reference><Reference><Citation>Hunter R.L., Cheng B., Choi D.Y., Liu M., Liu S., Cass W.A., Bing G. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J. Neurosci Res. 2009;87:1913&#x2013;1921. doi: 10.1002/jnr.22012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22012</ArticleId><ArticleId IdType="pmc">PMC2692550</ArticleId><ArticleId IdType="pubmed">19224579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko Y.-H., Kim S.-K., Kwon S.-H., Seo J.-Y., Lee B.-R., Kim Y.-J., Hur K.-H., Kim S.Y., Lee S.-Y., Jang C.-G. 7,8,4&#x2032;-Trihydroxyisoflavone, a Metabolized Product of Daidzein, Attenuates 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells. Biomol. Ther. 2019;27:363&#x2013;372. doi: 10.4062/biomolther.2018.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2018.211</ArticleId><ArticleId IdType="pmc">PMC6609108</ArticleId><ArticleId IdType="pubmed">30866601</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan K.S., Halang L., Woods I., Prehn J.H. A high-fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP-43A315T mutant C57BL6/J mice. Dis. Model Mech. 2016;9:1029&#x2013;1037. doi: 10.1242/dmm.024786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.024786</ArticleId><ArticleId IdType="pmc">PMC5047697</ArticleId><ArticleId IdType="pubmed">27491077</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming S.M., Ekhator O.R., Ghisays V. Assessment of Sensorimotor Function in Mouse Models of Parkinson&#x2019;s Disease. J. Vis. Exp. 2013;76:e50303. doi: 10.3791/50303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/50303</ArticleId><ArticleId IdType="pmc">PMC3727502</ArticleId><ArticleId IdType="pubmed">23851663</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyenet S.J., Furrer S.A., Damian V.M., Baughan T.D., La Spada A.R., Garden G.A. A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia. J. Vis. Exp. 2010;21:e1787. doi: 10.3791/1787.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/1787</ArticleId><ArticleId IdType="pmc">PMC3121238</ArticleId><ArticleId IdType="pubmed">20495529</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez F.J., Lafuente H., Rey-Santano M.C., Mielgo V.E., Gastiasoro E., Rueda M., Pertwee R.G., Castillo A.I., Romero J., Mart&#xed;nez-Orgado J. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr. Res. 2008;64:653&#x2013;658. doi: 10.1203/PDR.0b013e318186e5dd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e318186e5dd</ArticleId><ArticleId IdType="pubmed">18679164</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>